Geftinat (Gefitinib) 250 mg

Indicated for the treatment of adult patients with Non-Small Cell Lung Cancer (NSCLC):

• First-line treatment: For patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
• Subsequent treatment: For patients with continued disease progression after platinum-based chemotherapy.

Standard Dosage: One 250 mg tablet once daily.

⚠️ Administration Instructions:

• Can be taken with or without food.
• Take at approximately the same time each day.
• Difficulty swallowing? The tablet can be dispersed in half a glass of drinking water (do not crush it). Stir until dispersed and drink immediately.

🚫 Drug Interaction Warning: Avoid drugs that reduce stomach acid (PPIs like Omeprazole, H2-blockers), as they significantly reduce Geftinat absorption.

• Hypersensitivity to Gefitinib.
• Pregnancy and breastfeeding.
• Severe hepatic impairment.
• Patients known to be EGFR mutation-negative (lack of efficacy).

Common side effects (often manageable):

• Skin Rash (Acneiform): Very common. Indicates the drug is potent. Managed with topical antibiotics or moisturizers.
• Diarrhea: Usually mild to moderate.
• Paronychia: Nail bed infections or brittle nails.
• Dry skin.